ArticleJournal of neuro-oncology2025
Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyperArc™ (HA) automates both planning and delivery of single-isocenter VMAT radiosurgery (SRS) and was designed for complex multi-metastasis cases. The clinical effectiveness of treating benign intracranial tumors (BIT) with HA is unknown. We collected data on treatment planning, delivery, and clinical outcomes of BIT managed with SRS since HA deployment.
methodsPatients received SRS using HA from 2017 to 2021 at a single institution. Prescription dose was normalized to ≥ 99% of gross tumor volume without additional expansion. Treatments were delivered on Varian Edge linear accelerator with 10MV flattening-filter free beam at up to 2400 MU/min with high-definition multi-leaf collimator. Post-treatment imaging, toxicities, and outcomes were assessed.
results198 BIT targets (min = 0.1 cc, max = 58.9 cc) were treated. A large variety (n = 8) of BIT were treated with the most common pathologies being meningiomas (130), pituitary adenomas (30), and acoustic schwannomas (23). Nearly half (45.1%) were treated in a single fraction (12-22 Gy) versus 54.9% with fractionated SRS (24-35 Gy). Mean RTOG CI and Paddick GI were 1.12 and 3.31, respectively. A majority (74%) were treated with 3 arcs with mean treatments lasting 10.5 min. Mean FU was 2.6 years. 20 of 198 (10.1%) tumors progressed with mean time to failure being 2.1 years. Tumor progression occurred in 10.1%, mostly in recurent WHO II meningiomas. Of those that progressed, 19 were meningiomas with 17 being WHO grade 2 with prior surgery. Grade 3 + CNS toxicity was reported in 4.3% of patients, with 98.9 and 99.5% hearing and visual preservation, respectively.
conclusionsWithout any planning target volume expansion, HA efficiently delivers high-quality plans with sharp dose fall-off for a wide variety of BITs. Early clinical outcomes and toxicity are consistent with historical controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.